Skip Nav Destination
Issues
1 January 2000
ISSN 1078-0432
EISSN 1557-3265
Advances in Brief
Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study1
George J. Brewer; Robert D. Dick; Damanjit K. Grover; Virginia LeClaire; Michael Tseng; Max Wicha; Kenneth Pienta; Bruce G. Redman; Thierry Jahan; Vernon K. Sondak; Myla Strawderman; Gerald LeCarpentier; Sofia D. Merajver
Clinical Trials
A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 0771
Carolyn D. Britten; Eric K. Rowinsky; Sharyn D. Baker; Geoffrey R. Weiss; Lon Smith; Joseph Stephenson; Mace Rothenberg; Leslie Smetzer; Jeffrey Cramer; William Collins; Daniel D. Von Hoff; S. Gail Eckhardt
TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients1
Daniela Kandioler-Eckersberger; Carmen Ludwig; Margarethe Rudas; Sonja Kappel; Elisabeth Janschek; Catharina Wenzel; Hermine Schlagbauer-Wadl; Martina Mittlböck; Michael Gnant; Günter Steger; Raimund Jakesz
A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors1
Eric Van Den Neste; Dominique de Valeriola; Joseph Kerger; Harry Bleiberg; Zlatko Kusenda; Christiane Brassinne; Sylvie Bartholomeus; Jean Selleslags; Philippe Hennebert; Hilda Wythouck; Isabelle Cazenave; Florence Lefresne-Soulas; Martine Piccart
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis1
Rosalind van Stolk; Gary Stoner; William L. Hayton; Kenneth Chan; Barry DeYoung; Laura Kresty; Brian H. Kemmenoe; Paul Elson; Lisa Rybicki; James Church; Kim Provencher; Denise McLain; Ernest Hawk; Ben Fryer; Gary Kelloff; Ram Ganapathi; G. Thomas Budd
Patients Treated with Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor1
Stefano De Santis; Andrea Pace; Loredana Bove; Francesco Cognetti; Francesca Properzi; Marco Fiore; Viviana Triaca; Antonella Savarese; Maria Domenica Simone; Bruno Jandolo; Luigi Manzione; Luigi Aloe
Molecular Oncology, Markers, Clinical Correlates
Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas1
Charles A. Smith; Agnese A. Pollice; Ling-Ping Gu; Kathryn A. Brown; Sarita G. Singh; Laura E. Janocko; Ronald Johnson; Thomas Julian; David Hyams; Norman Wolmark; Lillian Sweeney; Jan F. Silverman; Stanley E. Shackney
Prognostic Significance of DNA Ploidy, S-Phase Fraction, and Tissue Levels of Aspartic, Cysteine, and Serine Proteases in Operable Gastric Carcinoma1
Antonio Russo; Viviana Bazan; Manuela Migliavacca; Ines Zanna; Carla Tubiolo; Francesca Maria Tumminello; Gabriella Dardanoni; Massimo Cajozzo; Pietro Bazan; Giuseppe Modica; Mario Latteri; Rosa Maria Tomasino; Giuseppe Colucci; Nicola Gebbia; Gaetano Leto
Experimental Therapeutics, Preclinical Pharmacology
E1A-mediated Paclitaxel Sensitization in HER-2/neu-overexpressing Ovarian Cancer SKOV3.ip1 through Apoptosis Involving the Caspase-3 Pathway1
Naoto T. Ueno; Chandra Bartholomeusz; John L. Herrmann; Zeev Estrov; Ruping Shao; Michael Andreeff; Janet Price; Ralph W. Paul; Pervin Anklesaria; Dihua Yu; Mien-Chie Hung
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.